search

1-20 of 42

Save search

Sort by

Sort Order Select

2 3

Journal Article

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4 Get access

PDF

Jason Fangusaro and others

Neuro-Oncology, noaf065, https://doi.org/10.1093/neuonc/noaf065

Published: 17 April 2025

Supplementary data

Journal Article

CTIM-01. OUTCOMES AND IMMUNE RESPONSES AFTER PEPTIDE VACCINATION TARGETING HUMAN CYTOMEGALOVIRUS ANTIGEN PP65 IN CHILDREN AND YOUNG ADULTS WITH RECURRENT HIGH-GRADE GLIOMA AND MEDULLOBLASTOMA: RESULTS OF A PHASE 1 TRIAL

PDF

Eric Thompson and others

Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii84, https://doi.org/10.1093/neuonc/noae165.0335

Published: 11 November 2024

Journal Article

CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)

PDF

Annick Desjardins and others

Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii87, https://doi.org/10.1093/neuonc/noae165.0346

Published: 11 November 2024

Journal Article

MDB-49. OUTCOMES OF SONIC HEDGEHOG (SHH) MEDULLOBLASTOMA (MB) IN CHILDREN AND ADULTS TREATED WITH RISK-ADAPTED THERAPY ON A PROSPECTIVE INTERNATIONAL PROTOCOL (SJMB12)

PDF

Amar J Gajjar and others

Neuro-Oncology, Volume 26, Issue Supplement_4, June 2024, Page 0, https://doi.org/10.1093/neuonc/noae064.498

Published: 18 June 2024

Journal Article

LGG-05. REPORT ON PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC)-029B, A PROSPECTIVE PHASE 2 CLINICAL TRIAL OF SELUMETINIB IN TREATING YOUNG PATIENTS WITH RECURRENT/PROGRESSIVE LOW-GRADE GLIOMA: NEW RESULTS ON STRATA 2, 5, AND 6 WITH UPDATED LONG-TERM SURVIVAL OUTCOMES ON STRATA 1, 3, AND 4

PDF

Jason Fangusaro and others

Neuro-Oncology, Volume 26, Issue Supplement_4, June 2024, Page 0, https://doi.org/10.1093/neuonc/noae064.398

Published: 18 June 2024

Journal Article

TRLS-14. PNOC022 REPORT: A COMBINATION THERAPY TRIAL USING AN ADAPTIVE PLATFORM DESIGN FOR PATIENTS WITH DIFFUSE MIDLINE GLIOMA AT INITIAL DIAGNOSIS, POST-RADIATION THERAPY, OR PROGRESSION

PDF

Cassie Kline and others

Neuro-Oncology, Volume 26, Issue Supplement_4, June 2024, Page 0, https://doi.org/10.1093/neuonc/noae064.167

Published: 18 June 2024

Journal Article

CTNI-24. CLINICAL ACTIVITY AND SAFETY OF THE RAF INHIBITOR TOVORAFENIB IN PATIENTS WITH OPTIC PATHWAY GLIOMAS IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY

PDF

Karsten Nysom and others

Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v79, https://doi.org/10.1093/neuonc/noad179.0306

Published: 10 November 2023

Journal Article

CTNI-37. CLINICAL ACTIVITY OF RAF INHIBITOR TOVORAFENIB ACCORDING TO PRIOR MAPK INHIBITOR TREATMENT IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY

PDF

Dong-Anh Khuong-Quang and others

Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v82–v83, https://doi.org/10.1093/neuonc/noad179.0319

Published: 10 November 2023

Journal Article

CTIM-09. PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG)

PDF

Annick Desjardins and others

Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v62–v63, https://doi.org/10.1093/neuonc/noad179.0249

Published: 10 November 2023

Journal Article

CTNI-84. PNOC022: A COMBINATION THERAPY TRIAL USING AN ADAPTIVE PLATFORM DESIGN FOR PATIENTS WITH DIFFUSE MIDLINE GLIOMAS (DMGS) AT INITIAL DIAGNOSIS, POST-RADIATION THERAPY AND AT TIME OF PROGRESSION

PDF

Cassie Kline and others

Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v97, https://doi.org/10.1093/neuonc/noad179.0365

Published: 10 November 2023

Journal Article

LGG-09. CLINICAL ACTIVITY OF PAN-RAF INHIBITOR TOVORAFENIB IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY

PDF

Lindsay Kilburn and others

Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i57, https://doi.org/10.1093/neuonc/noad073.219

Published: 12 June 2023

Journal Article

CTIM-15. RESULTS OF A PHASE IB TRIAL OF RECOMBINANT POLIO:RHINOVIRUS IMMUNOTHERAPY FOR RECURRENT PEDIATRIC HIGH GRADE GLIOMA

PDF

Eric Thompson and others

Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Pages vii62–vii63, https://doi.org/10.1093/neuonc/noac209.247

Published: 14 November 2022

Journal Article

CTNI-68. FIREFLY-1 (PNOC026): PHASE 2 STUDY OF PAN-RAF INHIBITOR TOVORAFENIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RAF-ALTERED RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA OR ADVANCED SOLID TUMORS

PDF

Lindsay Kilburn and others

Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii89, https://doi.org/10.1093/neuonc/noac209.333

Published: 14 November 2022

Journal Article

CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS)

PDF

Annick Desjardins and others

Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii65, https://doi.org/10.1093/neuonc/noac209.255

Published: 14 November 2022

Journal Article

EPID-22. MATERNAL USE OF TOBACCO, ALCOHOL, AND ILLICIT DRUGS DURING PREGNANCY AND ASSOCIATION WITH CHILDHOOD CANCER SUBTYPES

PDF

Courtney Wimberly and others

Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii114, https://doi.org/10.1093/neuonc/noac209.432

Published: 14 November 2022

Journal Article

QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE

PDF

Margaret Johnson and others

Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi189, https://doi.org/10.1093/neuonc/noab196.748